Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus-Reference-Cited by-同舟云学术

Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus

Published:2016-10-01 Issue:10 Volume:176 Page:1474
ISSN:2168-6106
Container-title:JAMA Internal Medicine
language:en
Short-container-title:JAMA Intern Med

Author:

Faillie Jean-Luc¹,Yu Oriana H.²,Yin Hui³,Hillaire-Buys Dominique⁴,Barkun Alan⁵,Azoulay Laurent⁶

Affiliation:

1. Laboratory of Biostatistics, Epidemiology, and Public Health (Equipe d’Acceuil 2415), Faculty of Medicine, University of Montpellier, Montpellier, France2Department of Medical Pharmacology and Toxicology, Montpellier University Hospital, Montpellier, France

2. Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada4Division of Endocrinology, Jewish General Hospital, Montreal, Quebec, Canada

3. Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada

4. Department of Medical Pharmacology and Toxicology, Montpellier University Hospital, Montpellier, France5Institut National de la Santé et de la Récherche Médicale (INSERM), Unité 1058, Faculty of Medicine, University Montpellier 1, Montpellier, France

5. Division of Gastroenterology, McGill University Health Centre, Montreal, Quebec, Canada

6. Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada7Department of Oncology, McGill University, Montreal, Quebec, Canada

Publisher

American Medical Association (AMA)

Subject

Internal Medicine

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Exploring Their Impact on Diabetes, Obesity, and Cardiovascular Health Through a Comprehensive Literature Review;Cureus;2024-09-01

2. A review of serious adverse events linked with GLP-1 agonists in type 2 diabetes mellitus and obesity treatment;Pharmacological Reports;2024-08-02

3. Unveiling the Potential Role of Glucagon-Like Peptide-1 (Glp-1) Receptor Agonists in Offering Protection of the Cardiovascular, Renal, and Neural Systems: An Updated Narrative Review;Cureus;2024-07-31

4. Modern Management of Cardiometabolic Continuum: From Overweight/Obesity to Prediabetes/Type 2 Diabetes Mellitus. Recommendations from the Eastern and Southern Europe Diabetes and Obesity Expert Group;Diabetes Therapy;2024-07-11

5. Dipeptidyl Peptidase-4 Inhibitors and the Risk of Gallbladder and Bile Duct Disease Among Patients with Type 2 Diabetes: A Population-Based Cohort Study;Drug Safety;2024-05-08